Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

1.700 +0.030 (+1.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves ISO 13485 Certification
Underscoring the company’s commitment to quality and excellence 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Nasdaq Listing Decision
Company granted extension to regain compliance with Nasdaq listing requirements 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Funding Agreement with Existing Investors
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedules 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract 
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.